Long‐term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity
Cancer · 15.07.2023 · 129 (14) · 2192-2200
DOI: 10.1002/cncr.34787 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 05.04.2023. Verfasst von Max J Gordon und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Cardiovascular Diseases, Hypertension, Heart Diseases. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
Continuous ibrutinib administration is needed to maintain efficacy in patients with chronic lymphocytic leukemia (CLL) and, as such, long‐term toxicity is a concern. The authors report the 5‐year follow‐up of patients with CLL who received treatment with ibrutinib with a focus on hypertension and cardiovascular toxicities.
Methods
Patient characteristics were assessed, including blood pressure, cardiovascular disease, disease progression, and death. Univariate logistic regression analysis assessed the relation of patient characteristics and the development of new or worsened hypertension. The incidence of hypertensive outcomes was evaluated using competing risk. Survival was estimated using the Kaplan–Meier method.
Results
Three hundred patients with CLL who were treated with ibrutinib on clinical trials were included. The median patient age at study enrollment was 65 years (range, 29–83 years). Seventy percent of patients were men, and 88% were Caucasian. Sixty‐nine percent of patients had hypertension at baseline, and 47% were on antihypertensive medication. Eighty‐eight percent had relapsed or refractory CLL. New‐onset and worsening hypertension were common, occurring in 68.5% and 38% of patients, respectively. Systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg was observed in 16.9% of patients. Hypertension was reversible after ibrutinib discontinuation. Older age, male sex, tobacco use, and chronic kidney disease were associated with ibrutinib‐related hypertension. Baseline hypertension was not associated with major adverse cardiovascular events in ibrutinib‐treated patients nor with event‐free or overall survival.
Conclusions
Hypertension is a common toxicity in patients with CLL who receive ibrutinib but is manageable in most patients. Other than chronic kidney disease, baseline cardiovascular disease did not affect ibrutinib‐related hypertension nor was hypertension associated with major adverse cardiovascular events or survival. Plain Language Summary Ibrutinib is an effective treatment for patients with chronic lymphocytic leukemia. Ibrutinib is a well tolerated therapy, however hypertension can develop or worsen in patients receiving ibrutinib and other cardiovascular events are significant challenges to the use of this drug. This may be particularly true in patients with heart disease. Short‐term side effects may worsen heart disease, but the long‐term impact is unknown. The long‐term results of ibrutinib on heart disease and hypertension are described.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine, Houston, Texas, USA.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Max J Gordon
Förderung
- NCI NIH HHS
Zitieren
APA
Gordon, M. J., Jones, J. E., George, B., Peterson, C., Burger, J. A., Jain, N., Keating, M., Wierda, W. G., Durand, J. B., & Ferrajoli, A. (2023). Long‐term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Cancer, 129(14), 2192-2200. https://doi.org/10.1002/cncr.34787
Vancouver
Gordon MJ, Jones JE, George B, Peterson C, Burger JA, Jain N, et al. Long‐term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Cancer. 2023;129(14):2192-2200. doi:10.1002/cncr.34787
BibTeX
@article{Gordon2023,
author = {Gordon, Max J and Jones, Jade E and George, Binsah and Peterson, Christine and Burger, Jan A and Jain, Nitin and Keating, Michael and Wierda, William G and Durand, Jean-Bernard and Ferrajoli, Alessandra},
title = {Long‐term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity},
journal = {Cancer},
year = {2023},
volume = {129},
number = {14},
pages = {2192--2200},
doi = {10.1002/cncr.34787}
}
EUVIMED